Desiree Matthews, PMHNP-BC gives a brief, clinical overview of the prevalence, symptoms, and diagnostic criteria for TD.
Supported by an educational grant from Neurocrine Biosciences, Inc.
Podcasts
All Podcasts
Desiree Matthews, PMHNP-BC, discusses what realistic treatment outcomes look like and how to talk about them with patients.
Jonathan Meyer, MD discusses age, sex, duration of treatment, comorbidities, and other risk factors.
Jonathan Meyer, MD discusses subtle movements that are easy to overlook and how to recognize them early.
Jonathan Meyer, MD compares first-generation and second-generation antipsychotics in TD risk.
Dr. Meyer discusses how dopamine receptor changes contribute to the development of tardive dyskinesia and the potentially detrimental effects of some treatments.
Transcript
Hello dear colleagues, welcome to this podcast.
Welcome back dear colleagues to a discussion on the topic of the hidden toll of tardive dyskinesia: beyond movement symptoms.
Welcome dear colleagues and welcome to this conversation on mastering VMAT2 inhibitors, the goal being optimizing treatment s